Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Filament Health Corp. (E:FH)

Business Focus: Advanced Medical Equipment & Technology (NEC)

Get the company report for the most recent outlook updated daily

Insider Chart - Past 6 Months

Insider Filings

Latest 10 SEDI filings for FH within the last 6 months
Loading...
See all filings within the past 6 months

Company News

Mar 19, 2024 07:30 ET
FILAMENT HEALTH ANNOUNCES SHIPMENTS OF BOTANICAL PSILOCYBIN TO FOUR COUNTRIES FOR CLINICAL INVESTIGATION
Research institutions in the United States, Canada, Israel, and Belgium, including Johns Hopkins University, will study PEX010, Filament's botanical psilocybin drug candidate
Read full article
Feb 15, 2024 06:30 ET
FILAMENT HEALTH COMPLETES THE FIRST EXPORT OF BOTANICAL PSILOCYBIN TO ISRAEL
Hadassah University Hospital will study PEX010, Filament's botanical psilocybin drug candidate, for the treatment of post-traumatic stress disorder and obsessive-compulsive disorder
Read full article
See more news stories

Valuation Ratios

Industry
Sector
Beta
N/A
--
--
Price to Sales - TTM
17.78
11.19
3.46
Price to Book - most recent quarter
4.06
2.66
2.02
Price to Cash Flow per share - TTM
--
9.43
9.70
Price to Free Cash Flow per share - TTM
--
--
12.33
See all valuations

Short Report

DateNumber of Shares ShortedNet Change
Mar 15, 20245,0754,045
Feb 29, 20241,030-1,390
Feb 15, 20242,420-153
See Short Report

Business Summary

Sector:  Healthcare Industry:  Advanced Medical Equipment & Technology

Filament Health Corp. is a Canada-based clinical-stage natural psychedelic drug development company. The Company's platform of proprietary intellectual property enables the discovery, development, and delivery of natural psychedelic medicines. The Company's first three botanical drug candidates are standardized, purified extracts of psilocybe cubensis fruiting bodies include: PEX010 Psilocybin - oral delivery (1mg and 25mg), PEX020 Psilocin - oral delivery (dose withheld), and PEX030 Psilocin - sublingual delivery (dose withheld). The Company's preclinical stage drug candidates include AEX010 Ayahuasca - oral delivery (dose withheld), and AEX020 Monoamine Oxidase Inhibitor - oral delivery (dose withheld). The Company's internal drug discovery and development program is carried out by its wholly owned subsidiary, Psilo Scientific Ltd., and is focused on developing standardized pharmaceutical-grade drug candidates from botanical psychedelic biomass.

See business summary

 

Twitter

Search (past week) for $FH.CA

  • No tweets found